Number of patients (person-years) in the registry cohorts: in the main cohort, in the nested sub-cohorts and remaining sensitivity analyses
| CORRONA | SRR | NOAR | CORRONA International | IORRA | |
|---|---|---|---|---|---|
| Main analysis | |||||
| Main cohort defined from 1 January 2000 | 24 176 (76 089) | 18 527 (81 648) | 1564 (10 970) | 3867 (3037) | 10 255 (62 345) |
| Sensitivity analyses | |||||
| Sub-cohorts defined based on inclusion criteria | |||||
| Sensitivity analysis 1: Active RA (patients with seropositive/erosive RA and with ≥4+4 tender/swollen joints) | 7267 (23 450) | 7268 (32 622) | 373 (2032) | 1106 (813) | 2703 (16 826) |
| Sensitivity analysis 2: Treatment switch/addition in biologic-naïve patients | 3079 (9790) | 5945 (25 449) | 364 (2035) | 285 (186) | 5250 (29 464) |
| Sensitivity analysis 3: Treatment switch/addition in patients previously treated with biologics | 3617 (10 075) | 1688 (5835) | NA | NA | NA |
| Sub-cohorts with additional restriction based on trial exclusion criteria | |||||
| Sensitivity analysis 4: Treatment switch/addition in biologic-naïve patients with trial exclusion criteria also applied | 2624 (8488) | 5022 (21 963) | 328 (1836) | 273 (178) | 5001 (28 302) |
| Sensitivity analysis 5: Treatment switch/addition in patients previously treated with biologics patients with trial exclusion criteria also applied | 3046 (8553) | 1409 (4922) | NA | NA | NA |
| Restrictions in calendar time period studied and in follow-up (truncated to 18 months) | |||||
| Sensitivity analysis 6: 2005 and onwards; main cohort defined from 1 January 2005 | 22 896 (65 030) | 17 186 (55 043) | 1439 (8943) | 3867 (3037) | 8457 (39 857) |
| Sensitivity analysis 7: Treatment switch/addition in biologic-naïve patients, with 18 months truncated follow-up | 3079 (3356) | 5945 (7877) | 364 (544) | 285 (185) | 5250 (7476) |
| Sensitivity analysis 8: Treatment switch/addition in patients previously treated with biologics, with 18 months truncated follow-up | 3617 (3870) | 1688 (2138) | NA | NA | NA |
| Additional standardisation | |||||
| Sensitivity analysis 9: Standardised for HAQ score category in addition to sex and age | 23 117 (72 264) | 16 712 (75 280) | 1535 (10 763) | 3572 (2704) | 10 234 (62 232) |
CORRONA, Consortium of Rheumatology Researchers of North America; HAQ, Health assessment questionnaire; IORRA, Institute of Rheumatology, Rheumatoid Arthritis; NA, Not available; NOAR, Norfolk Arthritis Register; RA, Rheumatoid arthritis; SRR, Swedish Rheumatology Quality of Care Register.